

Friday, 12 September

Saturday, 13 September

Sunday, 14 September

Monday, 15 September

****AGENDA topics and times subject to change****

Friday, 12 September

Time	Session/Topic
7:30	YIM Breakfast, Coffee, and Tea
8:00	Young Investigator Meeting
15:05	Young Investigator Meeting Concludes
18:30	iwCLL Welcome Reception

DAY 1 - Saturday, 13 September

Time	Session/Topic	Speakers
7:15	Breakfast, Coffee, and Tea	
8:15	Welcome and Introductions	Tadeusz Robak, MD, PhD Medical University of Łódź Łódź, Poland Iwona Hus, MD, PhD, DSc Department of Hematology, National Medical Institute Ministry of Interior and Administration Warsaw, Poland
8:25	Current Status and the Future of iwCLL	Thomas Kipps, MD, PhD UC San Diego, Moores Cancer Center La Jolla, California, United States

Theme 1: Pathogenesis of CLL

Session 1: Novel Insights Into the Pathogenesis of CLL		Session Co-Chairs Catherine Wu, MD Dana-Farber Cancer Institute Boston, Massachusetts United States Stephan Stilgenbauer, MD University of Ulm Ulm, Germany
8:40	Lymphoid CHP	Frederick Damm, MD Berlin School of Integrative Oncology Berlin, Germany
8:55	Insights Into Pathogenesis From Germline Predisposition/ Familial CLL Studies, Including MBL	Susan Slager, PhD Mayo Clinic Rochester, Minnesota United States
9:10	Targeting Repressive LEF1/b-Catenin Complexes in CLL	Markus Müschen, MD, PhD Yale University, Yale Cancer Center New Haven, Connecticut United States
9:25	Panel Discussion With Interactivity and Audience Q&A	
9:40	Oral/Poster Abstracts	
10:00	Morning Break	

DAY 1 - Saturday, 13 September (continued)

Time	Session/Topic	Speakers
Session 2: Genomics, Epigenetics, and Proteomics of CLL		Session Co-Chairs Thorsten Zenz, MD University Hospital Zurich Zurich, Switzerland Sarka Pospisilova, PhD Masaryk University Brno, Czech Republic
10:20	Clonal Evolution	Ferran Nadeu, PhD August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona, Spain
10:35	Epigenetics	Inaki Martin Subero, PhD August Pi i Sunyer Biomedical Research Institute (IDIBAPS) Barcelona, Spain
10:50	Proteomics	Fabienne Meier-Abt, MD, PhD University of Zurich Zurich, Switzerland
11:05	Metabolic Profile of CLL	Varsha Gandhi, PhD University of Texas MD Anderson Cancer Center Houston, Texas United States
11:20	Panel Discussion With Interactivity and Audience Q&A	
11:35	Oral/Poster Abstracts	
12:05	Lunch	
12:50	Industry Supported Symposium	
Session 3: Immunology and the Tumor Microenvironment		Session Co-Chairs Nicholas Chiorazzi, MD The Feinstein Institute for Medical Research Manhasset, New York United States Martina Seiffert, PhD German Cancer Research Center Heidelberg, Germany
13:55	Cell Trafficking in CLL	Tanja Hartmann, MD, PhD Medical Center, University of Freiburg Freiburg, Germany
14:10	Extracellular Vesicles in CLL	Etienne Moussay, PhD, ADR Luxembourg Institute of Health Luxembourg, Germany
14:25	Metabolic Reprogramming in the Tumor Microenvironment: The CLL and T cell Perspective	Eric Eldering, PhD Amsterdam University Medical Centres Amsterdam, Netherlands
14:40	Understanding the Role and Targeting the Non-Lymphoid Elements in the Tumor Microenvironment	Alan Ramsey, MD King's College London London, England
14:55	Panel Discussion With Interactivity and Audience Q&A	
15:10	Oral/Poster Abstracts	
15:30	Afternoon Break	

DAY 1 - Saturday, 13 September (continued)

Time	Session/Topic	Speakers
Session 4: Preclinical Studies of Novel Therapies		Session Co-Chairs Paolo Ghia, MD, PhD Università Vita Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele Milano, Italy Shih-Shih Chen, PhD Feinstein Institutes for Medical Research, Northwell Health Great Neck, New York United States
15:50	Exploring Siglec-6 as a Novel Target for Potential Therapeutic Utility in Chronic Lymphocytic Leukemia	Natarajan Muthusamy, PhD, DVM The Ohio State University Comprehensive Cancer Center Columbus, Ohio United States
16:05	A Pan-Cancer Single Cell RNA Seq Atlas of Intratumoral B Cells and T/B Cell Interaction	Tullia Bruno, PhD University of Pittsburgh Hillman Cancer Center Pittsburgh, Pennsylvania United States
16:20	Using Mouse Models to Test Therapeutic Strategies in Richter's Transformation	Elisa ten Hacken, PhD Weill Medical College of Cornell University New York, New York United States
16:35	Panel Discussion With Interactivity and Audience Q&A	
16:50	Oral/Poster Abstracts	
17:10	End of Day 1	

DAY 2 - Sunday, 14 September

Time	Session/Topic	Speakers
7:15	Breakfast, Coffee, and Tea	
Theme 2: Therapy of CLL		
Session 5: Management of Treatment Lines Throughout the Course of CLL		Session Co-Chairs Barbara Eichhorst, MD University of Cologne Cologne, Germany William Wierda, MD, PhD The University of Texas MD Anderson Cancer Center Houston, Texas United States
8:15	Goals of Treatment Aligning With Continuum of Disease and Impact of First-Line Choices	Jennifer Woyach, MD The Ohio State University Comprehensive Cancer Center Columbus, Ohio United States
8:35	Individualizing First-Line Treatment Choice Based on Patient and Disease Characteristics	Nitin Jain, MD The University of Texas MD Anderson Cancer Center Houston, Texas United States
8:55	Panel Discussion With Interactivity and Audience Q&A	
9:10	Oral/Poster Abstracts	

DAY 2 - Sunday, 14 September (continued)

Time	Session/Topic	Speakers
Session 6: How I Treat Double Relapsed/Refractory CLL		Session Co-Chairs Jennifer Brown, MD, PhD Dana-Farber Cancer Institute Boston, Massachusetts United States John Seymour, MBBS, PhD Peter MacCallum Cancer Centre Melbourne, Australia
9:30	Who Becomes/Are Double Refractory Patients?	Inhye Ahn, MD Dana Farber Cancer Institute Boston, Massachusetts United States
9:45	How Do I Treat Double Refractory Patients With Targeted Therapy?	Lindsey Roeker, MD Memorial Sloan Kettering Cancer Center New York, New York United States
10:00	How Do I Treat Double Refractory Patients With Cellular Therapy?	Philip Thompson, MBBS Peter MacCallum Cancer Centre and The Royal Melbourne Hospital Melbourne, Australia
10:15	Panel Discussion With Interactivity and Audience Q&A	
10:25	Oral/Poster Abstracts	
10:45	Morning Break	
11:00	Industry Supported Symposium	
Session 7: Richter Transformation		Session Co-Chairs Gianluca Gaidano, MD, PhD University of Eastern Piedmont Novara, Italy Silvia Deaglio, MD, PhD University of Turin Turin, Italy
12:05	Disease Profiling to Identify Potential Therapeutic Targets in Richters	Erin Parry, MD, PhD Dana-Farber Cancer Institute Boston, Massachusetts United States
12:20	Current State of the Art for the Treatment of Richter Syndrome	Othman Al-Sawaf, MD University Hospital of Cologne Cologne, Germany
12:35	Panel Discussion With Interactivity and Audience Q&A	
12:45	Oral/Poster Abstracts	
13:05	Lunch	
13:55	Industry Supported Symposium	
Session 8: Health Maintenance for Patients With CLL		Session Co-Chairs Carsten U. Niemann, MD Rigshospitalet, Copenhagen University Hospital Copenhagen, Denmark Brian Koffman, MDCM, MS Ed CLL Society, Inc. Chula Vista, California United States

DAY 2 - Sunday, 14 September (continued)

Time	Session/Topic	Speakers
15:00	Vaccination and Infection Prevention	Stephen Opat, MD Monash Health Victoria, Melbourne, Australia
15:10	Diet (including D vitamin) and Exercise	Tamar Tadmor, MD Technion-Israel Institute of Technology Haifa, Israel
15:20	Comorbidities and Impact on Time to Treatment	Emelie Curovic Rotbain, MD, PhD Rigshospitalet and Danish Cancer Society Copenhagen, Denmark
15:30	<i>Binet/Rai Medal Presentation</i>	
Session 9: CONCURRENT WORKSHOP BREAKOUTS		
15:40	WORKSHOP 1: Case Studies of Rare Symptoms and Complications in CLL Alessandra Ferrajoli, MD The University of Texas MD Anderson Cancer Center Houston, Texas United States Susan O'Brien, MD University of California, Irvine Orange, California United States Mazyar Shadman, MD, MPH Fred Hutch Cancer Center Seattle, Washington United States	
	WORKSHOP 2: Adaptive Trial Design for Testing Novel Agents Matthew Davids, MD, MMSc Dana-Farber Cancer Institute Boston, Massachusetts United States Susan M. Geyer, PhD Mayo Clinic Rochester, Minnesota Arnon Kater, MD, PhD Amsterdam University Medical Centers Amsterdam, Netherlands	
	WORKSHOP 3: New Technologies in CLL Diagnostics and Monitoring Response to Treatment Anton W. Langerak, PhD Erasmus MC Rotterdam, Netherlands Davide Rossi, MD, PhD Oncology Institute of Southern Switzerland Bellinzona, Switzerland Eugene Tausch, MD Ulm University Ulm, Germany	
16:40	Adjourn	
17:00	Wine and Cheese Poster Session Reception	

DAY 3 - Monday, 15 September

Time	Session/Topic	Speakers
7:15	Breakfast, Coffee, and Tea	
Session 10: Novel Therapies for CLL I: Non-Immunological Approaches		Session Co-Chairs Jennifer Woyach, MD The Ohio State University Comprehensive Cancer Center Columbus, Ohio United States Francesc Bosch, MD, PhD Hospital Universitari Vall d'Hebron Barcelona, Spain
8:15	The Emerging Promise of Targeted Protein Degraders	Alexey Danilov, MD, PhD City of Hope National Medical Center Duarte, California United States
8:30	BCR Pathway Targets Beyond BTK and PI3K	Deborah Stephens, DO University of North Carolina Chapel Hill, North Carolina United States
8:45	Targeting Surface Antigens	Kerry A. Rogers, MD The Ohio State University Comprehensive Cancer Center Columbus, Ohio United States
9:00	Newer Anti-Apoptosis Inhibitors	Jacob Soumerai, MD Harvard Medical School, Massachusetts General Hospital Boston, Massachusetts United States
9:15	Panel Discussion With Interactivity and Audience Q&A	
9:30	Oral/Poster Abstracts	
9:50	Morning Break	
Session 11: Novel Therapies for CLL II: Harnessing the Power of the Immune System to Combat CLL		Session Co-Chairs Maria Teresa Sabrina Bertilaccio, PhD The University of Texas MD Anderson Cancer Center Houston, Texas United States Arnon Kater, MD, PhD Amsterdam University Medical Centers Amsterdam, Netherlands
10:10	Bispecific Antibodies	Parag Jasani, MBBS, FRCP, FRCPath Royal Free London NHS Trust London, England
10:25	Other Approaches to Enhance Host Immune Disease Response: IMiDs and Peptide Vaccination Strategies	Helga Simon-Molas, PhD Amsterdam University Medical Centers Amsterdam, Netherlands
10:40	CD19 Targeted CAR-T: Autologous & Allogeneic	Jan Joseph (Jos) Melenhorst, PhD Cleveland Clinic Cleveland, Ohio United States
10:55	CAR Therapies: Beyond T-cells and CD19 as the Target	Sunil Acharya, PhD MD Anderson Cancer Center Houston, Texas United States

DAY 3 - Monday, 15 September (continued)

Time	Session/Topic	Speakers
11:10	Panel Discussion With Interactivity and Audience Q&A	
11:25	<i>Oral/Poster Abstracts</i>	
11:50	Lunch	
12:40	Keynote Presentation: Measurable Residual Disease in Chronic Lymphocytic Leukemia: Technical Aspects and Clinical Significance	Krzysztof JamroziaK, MD, PhD Institute of Hematology and Transfusion Medicine Warsaw, Poland
Session 12: Patient Experience and CLL in Resource Limited Countries		Session Co-Chairs Anna Schuh, MD, PhD, MRCP, FRCPath University of Oxford Oxford, United Kingdom Raul Gabus, MD Hospital Maciel - ASSE Montevideo, Uruguay
13:10	Winning Competitive Oral Abstracts	
13:40	Development of Resource Restricted Guidelines	Mazyar Shadman, MD, MPH Fred Hutch Cancer Center Seattle, Washington United States
13:50	A Global Registry for CLL Update	Kostas Stamatopoulos, MD, PhD CERTH, Institute of Applied Biosciences Thessaloniki, Greece
14:00	Patient Experience in LMICs	Catherina Scheepers The Max Foundation South Africa Andrielle Yost The Max Foundation Philadelphia, Pennsylvania United States
14:10	Panel Discussion With Interactivity and Audience Q&A	Panel including Catherine Moura, MD, MPH (virtually) Abrale - Brazilian Lymphoma and Leukemia Association Sao Paulo, Brazil Dina Steagall, MPA Abrale - Brazilian Lymphoma and Leukemia Association Sao Paulo, Brazil
14:25	Afternoon Break	
Session 13: Future Directions and Unmet Needs in CLL		Session Co-Chairs Thomas Kipps, MD, PhD UC San Diego, Moores Cancer Center La Jolla, California, United States Michael HalleK, MD University Hospital of Cologne, German CLL Study Group Cologne, Germany
14:50	Panel Discussion With Interactivity and Audience Q&A	
15:55	Closing Comments/iwCLL 2025 Awards/2027 Announcement	Tadeusz Robak, MD, PhD Medical University of Łódź Łódź, Poland
16:10	Close of Workshop	